Curi RMB Capital LLC Has $8.92 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Curi RMB Capital LLC reduced its stake in Gilead Sciences by 5.9%, owning 79,577 shares valued at approximately $8.9 million after selling 4,947 shares in the first quarter.
• Several institutional investors significantly increased their positions in Gilead Sciences, with Activest Wealth Management raising its stake by 2,837.5% and Core Alternative Capital increasing by 370.8% in the same period.
• Gilead Sciences declared a quarterly dividend of $0.79 per share, payable on September 29th, and has a current dividend yield of 2.8% with a payout ratio of 62.95%.

Curi RMB Capital LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,577 shares of the biopharmaceutical company's stock after selling 4,947 shares during the quarter. Curi RMB Capital LLC's holdings in Gilead Sciences were worth $8,917,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management lifted its holdings in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at about $29,000. Colonial Trust Advisors lifted its holdings in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares in the last quarter. Finally, Core Alternative Capital lifted its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Finally, UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $2.28 during mid-day trading on Friday, reaching $115.05. 6,953,644 shares of the company's stock were exchanged, compared to its average volume of 5,228,918. The firm has a market capitalization of $142.76 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a one year low of $78.26 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The business's fifty day simple moving average is $113.59 and its two-hundred day simple moving average is $109.91.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Insider Buying and Selling

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer directly owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $9,371,330. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.